BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Renal Cell ◽

Low Dose ◽

First Line ◽

Safety And Efficacy ◽

Bevacizumab (BEV) + Low-Dose Interferon-α2A (IFN) for First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC): Final Safety and Efficacy Data from the Prospective Bevlin Study

Annals of Oncology ◽

10.1016/s0923-7534(20)33377-9 ◽

2012 ◽

Vol 23 ◽

pp. ix267

Author(s):

B. Melichar ◽

S. Bracarda ◽

V. Matveev ◽

A. Kaprin ◽

B. Alekseev ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Low Dose ◽

Line Treatment ◽

First Line ◽

Efficacy Data ◽

Safety And Efficacy ◽

Interferon Α2a ◽

First Line Treatment

Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5095 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5095-5095 ◽

Cited By ~ 12

Author(s):

E. Bajetta ◽

A. Ravaud ◽

S. Bracarda ◽

S. Négrier ◽

C. Szczylik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Efficacy And Safety ◽

First Line ◽

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2018.10.001 ◽

2019 ◽

Vol 17 (1) ◽

pp. e150-e155 ◽

Cited By ~ 4

Author(s):

Cristina Masini ◽

Maria Giuseppa Vitale ◽

Marco Maruzzo ◽

Giuseppe Procopio ◽

Ugo de Giorgi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Renal Failure ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Safety And Efficacy

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

10.1038/sj.bjc.6605585 ◽

2010 ◽

Vol 102 (7) ◽

pp. 1196-1197 ◽

Cited By ~ 1

Author(s):

C Porta

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

10.1038/sj.bjc.6605887 ◽

2010 ◽

Vol 103 (8) ◽

pp. 1309-1310

Author(s):

G H J Mickisch ◽

B Escudier ◽

S Walzer ◽

M Nuijten

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

10.1038/sj.bjc.6605417 ◽

2009 ◽

Vol 102 (1) ◽

pp. 80-86 ◽

Cited By ~ 37

Author(s):

G Mickisch ◽

M Gore ◽

B Escudier ◽

G Procopio ◽

S Walzer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Annals of Oncology ◽

10.1093/annonc/mdx423 ◽

2017 ◽

Vol 28 ◽

pp. vi17

Author(s):

C. Masini ◽

M.G. Vitale ◽

M. Maruzzo ◽

G. Procopio ◽

U. De Giorgi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Renal Failure ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Safety And Efficacy

CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure

Annals of Oncology ◽

10.1093/annonc/mdx371.059 ◽

2017 ◽

Vol 28 ◽

pp. v321

Author(s):

C. Masini ◽

M.G. Vitale ◽

M. Maruzzo ◽

G. Procopio ◽

U. De Giorgi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Renal Failure ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

Safety And Efficacy

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

10.1038/sj.bjc.6605886 ◽

2010 ◽

Vol 103 (8) ◽

pp. 1307-1308 ◽

Cited By ~ 1

Author(s):

C Charbonneau ◽

R Sandin

Keyword(s):

Renal Cell Carcinoma ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

First Line ◽

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Annals of Oncology ◽

10.1093/annonc/mdt228 ◽

2013 ◽

Vol 24 (9) ◽

pp. 2396-2402 ◽

Cited By ~ 20

Author(s):

B. Melichar ◽

S. Bracarda ◽

V. Matveev ◽

B. Alekseev ◽

S. Ivanov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Low Dose ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Interferon Α2a ◽

First Line Treatment